bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Here’s Why

Shares of bioMerieux (OTCMKTS:BMXMF) gapped up before the market opened on Tuesday . The stock had previously closed at $83.17, but opened at $88.4950. bioMerieux shares last traded at $88.4950, with a volume of 106 shares traded.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BMXMF shares. Morgan Stanley lowered shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th. Zacks Research cut shares of bioMerieux from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Piper Sandler initiated coverage on shares of bioMerieux in a research report on Thursday, June 11th. They set a “neutral” rating for the company. Finally, UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Four research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, bioMerieux currently has a consensus rating of “Reduce”.

bioMerieux Stock Performance

The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The company has a fifty day moving average of $79.87 and a two-hundred day moving average of $93.15.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.